GC506 / FutureGen Biopharmaceutical, AstraZeneca - LARVOL DELTA

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells for Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Peking University

CAR T-Cell Therapy • New P1 trial • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor

Gracell Biotechnologies Acquisition Completed (GlobeNewswire) - "Gracell Biotechnologies Inc...today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the 'Merger Agreement'), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales ('Parent'), and Grey Wolf Merger Sub ('Merger Sub'), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent....The Company also announced today that it has requested that trading of the ADSs on the Nasdaq Global Select Market ('Nasdaq') be suspended as of February 22, 2024 (New York Time)."

M&A • Acute Lymphocytic Leukemia • Hematological Malignancies • Immunology • Leukemia • Lupus • Multiple Myeloma • Oncology • Solid Tumor • Systemic Lupus Erythematosus

Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) - "Gracell has long been dedicated to unlocking the tremendous potential of CAR-T therapy against solid tumors in our pursuit of transformative cell therapies....We look forward to advancing the clinical IIT evaluating SMART CART GC506 for the treatment of Claudin 18.2 positive tumors, building upon the success we have seen with Gracell’s work in hematologic cancers."

New trial • Solid Tumor

Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update (GlobeNewswire) - "On track to commence a China IIT for GC506 in Claudin18.2-positive solid tumors in the second quarter of 2023."

New trial • Oncology • Solid Tumor

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update (GlobeNewswire) - "Company-sponsored Phase 1/2 clinical trial in China evaluating GC012F in RRMM expected to initiate in the third quarter 2023....Plan to commence a China IIT for GC506 in Claudin18.2-positive solid tumors in first half of 2023."

New P1/2 trial • New trial • Oncology • Solid Tumor

Gracell Biotechnologies Reports Second Quarter 2022 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire) - "SMART CARTTM Platform: On track to commence patient enrollment in a China IIT for GC503 in mesothelin-positive solid tumors in 2022; Plan to commence a China IIT for GC506 in CLDN18.2-positive solid tumors."

New trial • Trial status • Oncology • Solid Tumor

Gracell Biotechnologies Reports Fourth Quarter and Full Year 2021 Unaudited Financial Results and Provides Corporate Update (GlobeNewswire) - "SMART CART^TM Platform: (i) On track to commence patient enrollment in a China IIT for GC503 in mesothelin-positive solid tumors including ovarian cancer in 2022; (ii) Plan to commence a China IIT for GC506 in CLDN18.2-positive solid tumors."

Enrollment status • New trial • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor